Antibodies News and Research

RSS

Crescendo raises additional £2M ($3.3M) in final close of Series A financing from EMBL Ventures

Crescendo Biologics Limited today announces it has raised a further £2m ($3.3m), from EMBL Ventures, in a final close of its Series A financing. Originally announced in December 2013, the Series A now totals £19.5m. It was led by Imperial Innovations and included new investor Astellas Venture Management. Founding seed investor Sofinnova Partners also contributed significantly to the round.

3 Apr 2014

Scientists identify new biomarker linked to non-small cell lung cancer, head and neck cancers

A team led by a scientist from the Florida campus of The Scripps Research Institute has identified a new biomarker linked to better outcomes of patients with head and neck cancers and non-small cell lung cancer. The work could help scientists develop new diagnostics and therapies and help physicians determine the best long-term treatments for patients with these cancers.

3 Apr 2014

Synthon’s SYD985 ADC demonstrates anti-tumor activity, outperforms leading anti-HER2 ADC

Synthon Biopharmaceuticals today announced the results of a head-to-head comparative program of its antibody-drug conjugate (ADC) SYD985 with Roche's market leading anti-HER2 ADC, T-DM1 (Kadcyla).

2 Apr 2014

FDA approves ORALAIR sublingual allergy immunotherapy tablet

GREER Laboratories, Inc., a leading developer and provider of allergy immunotherapy products and services, today announced that the U.S. Food and Drug Administration has approved ORALAIR (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) sublingual allergy immunotherapy tablet.

2 Apr 2014

Integral Molecular announces new patent protecting use of lipoparticles for eliciting antibodies against protein targets

Integral Molecular, a leader in membrane protein antibody discovery, announces the issuance of a new patent protecting the use of Lipoparticles for eliciting antibodies against membrane protein targets.

29 Mar 2014

$New instrument can conduct biological scans in fraction of time and cost of industry standard$

New instrument can conduct biological scans in fraction of time and cost of industry standard

Northeastern University professor of pharmaceutical sciences, Tania Konry, has developed a single instrument that can conduct a wide range of biological scans in a fraction of the time and cost of industry standard equipment. That's because it uses considerably less material and ultra-sensitive detection methods to do the same thing.

29 Mar 2014

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Today Biogen Idec announced that the U.S. Food and Drug Administration has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body.

29 Mar 2014

BIDMC scientist wins Gairdner Award for landmark discovery in the field of angiogenesis

Harold F. Dvorak, MD, senior investigator in the Center for Vascular Biology Research at Beth Israel Deaconess Medical Center and former chairman of BIDMC's Department of Pathology, is one of eight scientists to win the 2014 Canada Gairdner Awards, which recognize some of the most significant medical discoveries from around the world. Awarded by the Gairdner Foundation, based in Canada, the awards are considered among the most prestigious international awards in medical research.

29 Mar 2014

Two doses of HPV-16/18 AS04-adjuvanted vaccine Cervarix non-inferior to three-doses

A recent study in the journal Human Vaccines & Immunotherapeutics, showed that two doses of the HPV-16/18 AS04-adjuvanted vaccine Cervarix (GlaxoSmithKline) are non-inferior to three-doses in the current schedule.

29 Mar 2014

Researchers develop potentially safer and more cost-effective therapeutics against West Nile virus

An international research group led by Arizona State University professor Qiang "Shawn" Chen has developed a new generation of potentially safer and more cost-effective therapeutics against West Nile virus and other pathogens.

29 Mar 2014

ADMA Biologics reports consolidated net loss of $15.5M in 2013

ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its financial results for the year ended December 31, 2013 and provided recent company developments as well as anticipated milestones for 2014.

28 Mar 2014

$Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM$

Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM

Patrys Limited, a clinical stage biotechnology company, is pleased to announce the final results from its Phase I/IIa, open-label study in patients with refractory or relapsed multiple myeloma (MM).

28 Mar 2014

Research findings help explain rare genetic disorder that causes immunodeficiency syndrome

IRCM researchers led by Javier M. Di Noia, PhD, uncovered a new function of AID, a crucial enzyme for the immune response. The discovery, recently published by the scientific journal Proceedings of the National Academy of Sciences, helps explain a rare genetic disorder that causes an immunodeficiency syndrome.

28 Mar 2014

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA.

27 Mar 2014

Adaptimmune awarded £2.1 million grant to expedite development of engineered T cell therapy

Adaptimmune today announced that it has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. The prestigious award will expedite the development of Adaptimmune’s second engineered T cell therapy programme into the clinic in triple negative breast cancer.

26 Mar 2014

The Center for Applied Nanotechnology presents a ready-to-use reagent for the detection of poly-histidine tagged proteins in Blot assays

The nano-experts from the Center for Applied Nanotechnology (CAN) GmbH expand their product portfolio by CANdots® Series G - His Detect, which is a ready-to-use reagent for the detection of poly-histidine tagged proteins in Blot assays. It is easy to handle, highly sensitive as well as time saving compared to standard methods available on the market, e.g. ECL.

25 Mar 2014

Researchers develop one-step analysis for detecting tumor markers in blood

Benign growth, or cancer? Tumor markers in the blood help determine whether the patient is afflicted with a malign tumor and whether it is excreting markers more vigorously - involving highly specific proteins. An increased concentration in the blood provides one indication of the disease for physicians. However, it has been quite expensive in time and effort to detect the markers thus far. This is because all kinds of molecules and proteins are teeming in the blood. To be able to detect a single specific one, doctors must first separate and purify the blood in several steps, and then isolate the marker they are searching for from the rest of the molecules.

25 Mar 2014

Treatment with natalizumab in patients with MS appears linked with JC virus infection

Treatment with natalizumab in patients with multiple sclerosis (MS) appears linked with JC virus (JCV) infection, which can lead to a rare and often fatal demyelinating disease of the central nervous system called progressive multifocal leukoencephalopathy (PML) that destroys the myelin that protects nerve cells.

25 Mar 2014

Climate change could increase death rates in London and southeast England, scientists predict

Warmer summers brought on by climate change will cause more deaths in London and southeast England than the rest of the country, scientists predict.

24 Mar 2014

NIH awarded five-year grant of up to $28 million to fight deadly Ebola virus

The National Institutes of Health (NIH) has awarded a five-year grant of up to $28 million to establish a new center for excellence to find an antibody "cocktail" to fight the deadly Ebola virus.

21 Mar 2014

Antibodies News and Research

Crescendo raises additional £2M ($3.3M) in final close of Series A financing from EMBL Ventures

Scientists identify new biomarker linked to non-small cell lung cancer, head and neck cancers

Synthon’s SYD985 ADC demonstrates anti-tumor activity, outperforms leading anti-HER2 ADC

FDA approves ORALAIR sublingual allergy immunotherapy tablet

Integral Molecular announces new patent protecting use of lipoparticles for eliciting antibodies against protein targets

New instrument can conduct biological scans in fraction of time and cost of industry standard

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

BIDMC scientist wins Gairdner Award for landmark discovery in the field of angiogenesis

Two doses of HPV-16/18 AS04-adjuvanted vaccine Cervarix non-inferior to three-doses

Researchers develop potentially safer and more cost-effective therapeutics against West Nile virus

ADMA Biologics reports consolidated net loss of $15.5M in 2013

Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM

Research findings help explain rare genetic disorder that causes immunodeficiency syndrome

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

Adaptimmune awarded £2.1 million grant to expedite development of engineered T cell therapy

The Center for Applied Nanotechnology presents a ready-to-use reagent for the detection of poly-histidine tagged proteins in Blot assays

Researchers develop one-step analysis for detecting tumor markers in blood

Treatment with natalizumab in patients with MS appears linked with JC virus infection

Climate change could increase death rates in London and southeast England, scientists predict

NIH awarded five-year grant of up to $28 million to fight deadly Ebola virus

How to make hybridoma-based antibody discovery more efficient eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo